Brokerages Set Altimmune, Inc. (NASDAQ:ALT) PT at $18.80

Altimmune, Inc. (NASDAQ:ALT) has been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $18.80.

ALT has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Thursday, August 22nd. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. Piper Sandler reissued an “overweight” rating and issued a $25.00 target price on shares of Altimmune in a report on Friday, June 21st. Finally, B. Riley reaffirmed a “buy” rating and set a $20.00 price target on shares of Altimmune in a research note on Monday, August 12th.

Altimmune Stock Performance

NASDAQ:ALT opened at $6.20 on Wednesday. Altimmune has a 1 year low of $2.09 and a 1 year high of $14.84. The stock has a fifty day moving average price of $6.65 and a two-hundred day moving average price of $7.67. The stock has a market capitalization of $439.59 million, a price-to-earnings ratio of -3.90 and a beta of 0.08.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Altimmune had a negative net margin of 24,778.97% and a negative return on equity of 53.09%. The company had revenue of $0.01 million during the quarter. During the same period last year, the business earned ($0.32) EPS. On average, analysts predict that Altimmune will post -0.54 EPS for the current year.

Insider Buying and Selling

In other Altimmune news, Director David Drutz sold 16,011 shares of the business’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $6.90, for a total value of $110,475.90. Following the completion of the transaction, the director now directly owns 41,958 shares in the company, valued at approximately $289,510.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.10% of the stock is owned by company insiders.

Institutional Trading of Altimmune

Hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD grew its stake in shares of Altimmune by 13.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,238 shares of the company’s stock valued at $156,000 after buying an additional 1,821 shares during the period. North Star Investment Management Corp. acquired a new position in Altimmune in the first quarter valued at $31,000. Russell Investments Group Ltd. grew its position in Altimmune by 1,150.9% during the fourth quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company’s stock valued at $48,000 after acquiring an additional 3,959 shares during the period. CANADA LIFE ASSURANCE Co acquired a new stake in Altimmune during the first quarter worth about $44,000. Finally, TFO Wealth Partners LLC purchased a new position in shares of Altimmune in the 1st quarter worth about $51,000. 78.05% of the stock is owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.